CARLOS MANUEL
PANIZO SANTOS
Hospital Vall d'Hebron
Barcelona, EspañaPublicaciones en colaboración con investigadores/as de Hospital Vall d'Hebron (11)
2024
-
Polatuzumab vedotin plus rituximab and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study
The Lancet Haematology, Vol. 11, Núm. 2, pp. e136-e146
2023
-
Low-risk HPLLs/ABC score patients with splenic marginal zone lymphoma can be safely managed without treatment: Results from a prospective Spanish study
British Journal of Haematology, Vol. 202, Núm. 4, pp. 776-784
-
Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphoma
Blood Advances, Vol. 7, Núm. 17, pp. 4926-4935
2022
-
A randomized phase II study comparing consolidation with a single dose of 90Y ibritumomab tiuxetan vs. maintenance with rituximab for two years in patients with newly diagnosed follicular lymphoma responding to R-CHOP. Long-term follow-up results
Leukemia and Lymphoma, Vol. 63, Núm. 1, pp. 93-100
-
Autologous stem-cell transplantation as consolidation of first-line chemotherapy in patients with peripheral T-cell lymphoma: a multicenter GELTAMO/FIL study
Haematologica, Vol. 107, Núm. 11, pp. 2675-2684
2020
-
Avadomide monotherapy in relapsed/refractory DLBCL: safety, efficacy, and a predictive gene classifier
Blood, Vol. 135, Núm. 13, pp. 996-1007
-
RELINF: prospective epidemiological registry of lymphoid neoplasms in Spain. A project from the GELTAMO group
Annals of Hematology, Vol. 99, Núm. 4, pp. 799-808
2019
-
Burkitt-like lymphoma with 11q aberration: A germinal center-derived lymphoma genetically unrelated to Burkitt lymphoma
Haematologica, Vol. 104, Núm. 9, pp. 1822-1829
2018
-
Spanish Lymphoma Group (GELTAMO) guidelines for the diagnosis, staging, treatment, and follow-up of diffuse large B-cell lymphoma
Oncotarget, Vol. 9, Núm. 64, pp. 32383-32399
2015
-
Evaluation of clinical and biological prognostic factors in relapsed or refractory diffuse large B-cell lymphoma patients after previous treatment with rituximab and chemotherapy: Results of the PRO-R-IPI study
Clinical Lymphoma, Myeloma and Leukemia, Vol. 15, Núm. 7, pp. 398-403
2012
-
Clinical experience of bendamustine treatment for non-Hodgkin lymphoma and chronic lymphocytic leukemia in Spain
Leukemia Research, Vol. 36, Núm. 6, pp. 709-714